RT Journal Article
SR Electronic
T1 Risk factors for severe respiratory syncytial virus infection during the first year of life: development and validation of a clinical prediction model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.23.23286237
DO 10.1101/2023.02.23.23286237
A1 Vartiainen, Pekka
A1 Jukarainen, Sakari
A1 Rhedin, Samuel Arthur
A1 Prinz, Alexandra
A1 Hartonen, Tuomo
A1 Vabalas, Andrius
A1 Viippola, Essi
A1 Rodosthenous, Rodosthenis S.
A1 Kuitunen, Sara
A1 Liu, Aoxing
A1 Lundholm, Cecilia
A1 Smew, Awad I.
A1 Osvald, Emma Caffrey
A1 Helle, Emmi
A1 Perola, Markus
A1 Almqvist, Catarina
A1 Heinonen, Santtu
A1 Ganna, Andrea
YR 2023
UL http://medrxiv.org/content/early/2023/02/24/2023.02.23.23286237.abstract
AB Background Novel immunisation methods against respiratory syncytial virus (RSV) are emerging, but knowledge of risk factors for severe RSV disease is insufficient for their optimal targeting. We aimed to identify predictors for RSV hospitalisation, and to develop and validate a clinical prediction model to guide RSV immunoprophylaxis for under 1-year-old infants.Methods In this retrospective cohort study using nationwide registries, we studied all infants born in 1997-2020 in Finland (n = 1 254 913) and in 2006-2020 in Sweden (n = 1 459 472), and their parents and siblings. We screened 1 510 candidate predictors and we created a logistic regression model with 16 predictors and compared its performance to a machine learning model (XGboost) using all 1 510 candidate predictors.Findings In addition to known predictors such as severe congenital heart defects (CHD, adjusted odds ratio (aOR) 2·89, 95% confidence interval 2·28-3·65), we identified novel predictors for RSVH, most notably esophageal malformations (aOR 3·11, 1·86-5·19) and lower complexity CHDs (aOR 1·43, 1·25-1·63).In validation data from 2018-2020, the C-statistic was 0·766 (0·742-0·789) in Finland and 0·737 (0·710-0·762) in Sweden. The clinical prediction model’s performance was similar to the machine learning model (C-statistic in Finland 0·771, 0·754-0·788). Calibration varied according to epidemic intensity. Model performance was similar across different strata of parental income.The infants in the 90th percentile of predicted RSVH probability hospitalisation had 3·3 times higher observed risk than the population’s average. Assuming 60% effectiveness, immunisation in this top 10% of infants at highest risk would have a number needed to treat of 23 in Finland and 40 in Sweden in preventing hospitalisations.Interpretation The identified predictors and the prediction model can be used in guiding RSV immunoprophylaxis in infants.Funding Sigrid Jusélius Foundation, European Research Council, Pediatric Research Foundation (for complete list of funding sources, see Acknowledgements).Competing Interest StatementAll authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work not listed in "Funding". SH reports being the Site principal investigator in the MK1654-007 study, and sub-investigator in several maternal RSV vaccine and other pediatric vaccine trials at Meilahti Vaccine Research Center (MeVac), Helsinki, Finland; otherwise no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. SH reports lecture fees from Merck Sharp and Dohme, and Swedish Orphan Biovitrum; no other relationships or activities that could appear to have influenced the submitted work.Clinical Protocols https://osf.io/h7r9b Funding StatementThis study was funded by the Finnish Pediatric Research Foundation (Grant No 4970), the Sigrid Juselius Foundation (Grant No 220024) and Finnish Medical foundation. The FinRegistry project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 945733), starting grant AI-Prevent. SJ was supported by the Academy of Finland (grant no. 341747). SH was supported by the Academy of Finland (grant no. 323499). Financial support was provided from the Swedish Research Council (grant no 2018-02640), the Swedish Heart-Lung Foundation (grant no 20210416), the Foundation Frimurare Barnhuset in Stockholm, Ake Wiberg foundation, Karolinska Institutet and the Society of Child Care. SAR was supported by Region Stockholm (clinical postdoctorial appointment). The sponsor and funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:FinRegistry is a joint project of the Finnish Institute for Health and Welfare (THL) and the Data Science Genetic Epidemiology research group at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki. The FinRegistry project has received the following approvals for data access from the National Institute of Health and Welfare (THL/1776/6.02.00/2019 and subsequent amendments), Digital and population data services agency DVV (VRK/5722/2019-2), Finnish Center for Pension (ETK/SUTI 22003) and Statistics Finland (TK-53-1451-19). The FinRegistry project has received IRB approval from the National Institute of Health and Welfare (Kokous 7/2019). The study was also approved by the Swedish Ethical Review Authority (Dnr 2018/1697-31/1 and Dnr 2022-05010-02).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code of this project (including the clinical prediction model equation) is available in the FinRegistry GitHub at: https://github.com/dsgelab/rsv. Access to FinRegistry data can be obtained by submitting a data permit application for individual-level data for the Finnish social and health data permit authority Findata (https://asiointi.findata.fi/). The requests are evaluated on a case-by-case basis. Once approved, the data are sent to a secure computing environment Kapseli and can be accessed within the European Economic Area (EEA) and within countries with an adequacy decision from the European Commission. Data dictionaries for FinRegistry are publicly available on the FinRegistry website (www.finregistry.fi/finnish-registry-data). https://github.com/dsgelab/rsv